0001140361-17-001760.txt : 20170112
0001140361-17-001760.hdr.sgml : 20170112
20170112215916
ACCESSION NUMBER: 0001140361-17-001760
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170110
FILED AS OF DATE: 20170112
DATE AS OF CHANGE: 20170112
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abdun-Nabi Daniel
CENTRAL INDEX KEY: 0001380187
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 17526319
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DRIVE
STREET 2: SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4
1
doc1.xml
FORM 4
X0306
4
2017-01-10
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380187
Abdun-Nabi Daniel
400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG
MD
20879
1
1
0
0
President and CEO
Common Stock
2016-08-01
4
J
0
1979
0.0
A
172945
D
Common Stock
2016-08-01
4
J
0
3032
0.00
A
175977
D
Common Stock
2016-08-01
4
J
0
3419
0.00
A
179396
D
Common Stock
2017-01-10
4
M
0
38006
14.51
A
217402
D
Common Stock
2017-01-10
4
S
0
28240
31.2782
D
189162
D
Stock Option (Right to buy)
14.51
2016-08-01
4
J
0
3662
0
A
2017-03-08
Common Stock
3662
41668
D
Stock Option (Right to buy)
14.51
2017-01-10
4
M
0
38006
0
A
2017-03-08
Common Stock
38006
3662
D
In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in March 2017.
In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018.
In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019.
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.26, inclusive.
Represents options to purchase Emergent common stock awarded to the reporting person prior to the Spin-off . In connection with the Spin-off, the number of shares and exercise price of the option was adjusted, to preserve the pre-Spin-off intrinsic value of the existing Emergent option award.
Consists of an option granted under the company's stock incentive plan as amended and restated prior to the Spin-off.
The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.
/s/ Eric Burt, Attorney-in-fact
2017-01-10